These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Design and application of oncolytic viruses for cancer immunotherapy. Ylösmäki E; Cerullo V Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe? Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246 [TBL] [Abstract][Full Text] [Related]
4. The two-faces of NK cells in oncolytic virotherapy. Marotel M; Hasim MS; Hagerman A; Ardolino M Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674 [TBL] [Abstract][Full Text] [Related]
5. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Marchini A; Scott EM; Rommelaere J Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469 [TBL] [Abstract][Full Text] [Related]
6. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China. Wei D; Xu J; Liu XY; Chen ZN; Bian H Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308 [TBL] [Abstract][Full Text] [Related]
7. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z Front Immunol; 2022; 13():1012806. PubMed ID: 36311790 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250 [TBL] [Abstract][Full Text] [Related]
9. The Multifaceted Role of Macrophages in Oncolytic Virotherapy. Hofman L; Lawler SE; Lamfers MLM Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439 [TBL] [Abstract][Full Text] [Related]
10. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801 [TBL] [Abstract][Full Text] [Related]
11. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Feola S; Russo S; Ylösmäki E; Cerullo V Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. Russell L; Peng KW; Russell SJ; Diaz RM BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623 [TBL] [Abstract][Full Text] [Related]
14. The emerging field of oncolytic virus-based cancer immunotherapy. Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738 [TBL] [Abstract][Full Text] [Related]
15. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087 [TBL] [Abstract][Full Text] [Related]
16. Determinants of the efficacy of viro-immunotherapy: A review. de Graaf JF; Huberts M; Fouchier RAM; van den Hoogen BG Cytokine Growth Factor Rev; 2020 Dec; 56():124-132. PubMed ID: 32919831 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark. Muscolini M; Tassone E; Hiscott J Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166 [TBL] [Abstract][Full Text] [Related]
18. Going viral with cancer immunotherapy. Lichty BD; Breitbach CJ; Stojdl DF; Bell JC Nat Rev Cancer; 2014 Aug; 14(8):559-67. PubMed ID: 24990523 [TBL] [Abstract][Full Text] [Related]
19. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092 [TBL] [Abstract][Full Text] [Related]
20. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages. Shen Z; Liu X; Fan G; Na J; Liu Q; Lin F; Zhang Z; Zhong L J Transl Med; 2023 Nov; 21(1):842. PubMed ID: 37993941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]